Thyroid nodules: euthyroid, thyroid dysfunction and suspected cancer (Guidelines) | Right Decisions

Right Decisions
TAM (Treatments and Medicines) NHS Highland
ADULT THERAPEUTIC GUIDELINES
Back
ENDOCRINE
Thyroid nodules: euthyroid, thyroid dysfunction and suspected cancer (Guidelines)

Announcements and latest updates

Welcome to the Right Decision Service (RDS) newsletter for August 2024.

Contingency planning for RDS outages

Following the recent RDS outages, Tactuum and the RDS team have been reviewing the learning from these incidents. We are committed to doing all we can to ensure a positive outcome by strengthening the RDS to make it fully robust and clinically resilient for the future.

We would like to invite you to a webinar on 26^th September 3-4 pm on national and local contingency planning for future RDS outages. Tactuum and the RDS team will speak about our business continuity plans and the national contingency arrangements we are putting in place. This will also be a space to share local contingency plans, ideas and existing good practice. We would also like to gather your views on who we should send communications to in the event of future outages.

I have sent a meeting request for this date to all editors – please accept or decline to indicate attendance, and please forward on to relevant contacts. You can also contact Olivia.graham@nhs.scot directly to register your interest in participating.

2.National IV fluid prescribing calculator

This UK CA marked calculator is now live at https://righdecisions.scot.nhs.uk/ivfluids . It has been developed by a multiprofessional steering group of leads in IV fluids management, as part of the wider Modernising Patient Pathways Programme within the Centre for Sustainable Delivery. It aims to address a known cause of clinical error in hospital settings, and we hope it will be especially useful to the new junior doctors who started in August.

Please do spread the word about this new calculator and get in touch with any questions.

New toolkits

The following toolkits are now live;

Gender identity healthcare: adults and young people standards. (https://rightdecisions.scot.nhs.uk/genderidentity ) Note that this toolkit includes self-evaluation forms for each standard. A Scottish Government launch of these standards, together with the toolkit and NES educational resources, is planned for 3^rd September.
Care Inspectorate staffing method framework.
Vascular surgery pathways from the Modernising Patient Pathways Programme within the Centre for Sustainable Healthcare Delivery.

Updated guidance on current and future Medical Device Regulations

We have updated and simplified this guidance within our standard operating procedures. We have clarified the guidance on how to determine whether an RDS tool is a medical device, and have provided an interactive powerpoint slideset to steer you through the process.

Guide to six stages of RDS toolkit development

We have developed a guide to support editors and toolkit leads through the process of scoping, designing, delivering, quality assuring and implementing a new RDS toolkit. We hope this will help in project planning and in building shared understanding of responsibilities throughout the full development process. The guide emphasises that the project does not end with launch of the new toolkit. Implementation, communication and evaluation are ongoing activities throughout the lifetime of the toolkit.

Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

Thursday 5 September 1-2 pm
Wednesday 24 September 4-5 pm
Friday 27 September 12-1 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

7 Evaluation projects

Dr Stephen Biggart from NHS Lothian has kindly shared with us the results of a recent survey of use of the Edinburgh Royal Infirmary of Edinburgh Anaesthesia toolkit. This shows that the majority of consultants are using it weekly or monthly, mainly to access clinical protocols, with a secondary purpose being education and training purposes. They tend to find information by navigating by specialty rather than keyword searching, and had some useful recommendations for future development, such as access to quick reference guidance.

We’d really appreciate you sharing any other local evaluations of RDS in this way – it all helps to build the evidence base for impact.

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Treatment

CARBIMAZOLE tablets 5mg, 20mg

Dose: The initial dose can range from 5 to 40mg daily depending on the degree of hyperthyroidism, with repeat thyroid function usually after 4 weeks. The dose may then be progressively reduced to the lowest dose to maintain thyroid function within range. If unclear which dose to initiate, endocrinology can advise on receipt of referral, or seperately via Clinical Dialogue. Please note that propylthiouracil is the antithyroid drug of choice in the first trimester of pregnancy.

See Highland Formulary: Antithyroid drugs

Levothyroxine

Levothyroxine (T4) should be initiated once daily at a dose of 0.8 to 1.6 micrograms/kg, which is usually 50 to 125 micrograms. A lower dose should be used for elderly patients and patients with cardiac disease. It must be taken on an empty stomach, with no food consumption for 30 minutes. Not taking it in this way may prevent optimised treatment.

The aims of treatment are to manage the patient's hypothyroid symptoms and maintain thyroid stimulating hormone (TSH) levels within the normal range. If the TSH levels are too low then there is an increased risk of developing atrial fibrillation and osteoporosis. If the aims of treatment are not achieved with levothyroxine then the following should be checked:

Is the dose correct for the weight of the patient?
Is the treatment being taken correctly on an empty stomach?
Are there other treatments that might impair absorption (antacids, proton pump inhibitors, histamine-2-receptor antagonists)?
Are there other undiagnosed endocrine or auto-immune conditions?
Are there other causes of fatigue (depression, fibromyalgia, etc)?

These factors should be taken into account for any patient being considered for liothyronine (T3) treatment and when reviewing existing patients. Liothyronine must only be initiated by an endocrinologist.

Further information

Further information is available from the British Thyroid Association – Management of Primary Hypothyroidism & FAQs for GPs

Last reviewed: 31/08/2020

Next review date: 31/08/2023

Author(s): Endocrine .

Version: 2.1

Approved By: TAM subgroup of ADTC

Reviewer name(s): Dr A Isa, Consultant ENT Surgeon.

Document Id: TAM184